Immunotherapy for tularemia

Virulence

Volumn 4, Issue 8, 2013, Pages 859-870

  Skyberg, Jerod A ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Biodefense; Francisella; Immunity; Immunotherapy; Pathogen; Tularemia

Indexed keywords

ACAI DERIVED POLYSACCHARIDE; ANTISERUM; BCG VACCINE; BIOLOGIC FACTORS AND AGENTS ACTING ON THE IMMUNE SYSTEM; CATIONIC LIPOSOME DNA COMPLEX; DNA DEPENDENT ACTIVATOR INTERFERON REGULATORY FACTOR; ENDOTOXIN; GAMMA INTERFERON; GENTAMICIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; LEVOFLOXACIN; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN FRACTION; POLYINOSINIC POLYCYTIDYLIC ACID; RECOMBINANT BETA INTERFERON; RECOMBINANT INTERLEUKIN 12; TILORONE; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; TULAREMIA VACCINE; TUMOR NECROSIS FACTOR ALPHA; U112 LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; IMMUNOGLOBULIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BIOLOGICAL WARFARE; FRANCISELLA TULARENSIS; HUMAN; IMMUNITY; IMMUNOTHERAPY; NONHUMAN; TULAREMIA; BIODEFENSE; BIOLOGICAL WARFARE AGENT; FRANCISELLA; IMMUNOLOGY; MEDICAL RESEARCH; METHODOLOGY; PATHOGENESIS; REVIEW;

FRANCISELLA; FRANCISELLA TULARENSIS; NEGIBACTERIA;

BIODEFENSE; FRANCISELLA; IMMUNITY; IMMUNOTHERAPY; PATHOGEN; TULAREMIA;

BIOLOGICAL WARFARE AGENTS; BIOMEDICAL RESEARCH; FRANCISELLA TULARENSIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; TULAREMIA;

EID: 84888345044     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.25454     Document Type: Article

References (105)

1. Francis E. Tularemia. JAMA 1925; 278:1243-50; http://dx.doi.org/10.1001/jama.1925.02660430001001
2. Hong KJ, Wickstrum JR, Yeh HW, Parmely MJ. Toll-like receptor 2 controls the gamma interferon response to Francisella tularensis by mouse liver lymphocytes. Infect Immun 2007; 75:5338-45; PMID:17785474; http://dx.doi.org/10.1128/IAI.00561-07
3. Lake GC, Francis E. Six cases of tularemia occurring in laboratory workers. Public Health Rep 1922; 37:392-413; http://dx.doi.org/10.2307/4576294
4. Sewell DL. Laboratory-associated infections and biosafety. Clin Microbiol Rev 1995; 8:389-405; PMID:7553572
5. Oyston PC. Francisella tularensis: unravelling the secrets of an intracellular pathogen. J Med Microbiol 2008; 57:921-30; PMID:18628490; http://dx.doi.org/10.1099/jmm.0.2008/000653-0
6. Aquino LL, Wu JJ. Cutaneous manifestations of category A bioweapons. J Am Acad Dermatol 2011; 65:e1, e15; PMID:21777993; http://dx.doi.org/10.1016/j.jaad.2010.08.040
7. Evans ME. Francisella tularensis. Infect Control 1985; 6:381-3; PMID:3850862
8. Dennis DT. Tularemia. In: Wallace RB, ed. MaxcyRosenau-Last Public Health and Preventive Medicine. 14th edition. Stamford, CT: Appleton & Lange. 1998:354-57.
9. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al.; Working Group on Civilian Biodefense. Tularemia as a biological weapon: medical and public health management. JAMA 2001; 285:2763-73; PMID:11386933; http://dx.doi.org/10.1001/jama.285.21.2763
10. Allen LA, McCaffrey RL. To activate or not to activate: distinct strategies used by Helicobacter pylori and Francisella tularensis to modulate the NADPH oxidase and survive in human neutrophils. Immunol Rev 2007; 219:103-17; PMID:17850485; http://dx.doi.org/10.1111/j.1600-065X.2007.00544.x
11. Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S. Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med 1961; 107:702-14; PMID:13746667; http://dx.doi.org/10.1001/archinte.1961.03620050068007
12. McCrumb FR Jr, Snyder MJ, Woodward TE. Studies on human infection with Pasteurella tularensis; comparison of streptomycin and chloramphenicol in the prophylaxis of clinical disease. Trans Assoc Am Physicians 1957; 70:74-9, discussion 79-80; PMID:13496116
13. WHO Consultant Group. Health aspects of chemical and biological weapons. 1970; 105-7.
14. Kaufmann AF, Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack: are prevention and post attack intervention programs justifiable? Emerg Infect Dis 1997; 3:83-94; PMID:9204289; http://dx.doi.org/10.3201/eid0302.970201
15. Harris S. Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann N Y Acad Sci 1992; 666:21-52; PMID:1297279; http:// dx.doi.org/10.1111/j.1749-6632.1992.tb38021.x
16. Alibek K, Handelman S. Biohazard. New York, NY: Random House. 1999: 29-38.
17. Croddy E, Krcálová S. Tularemia, biological warfare, and the battle for Stalingrad (1942-1943). Mil Med 2001; 166:837-8; PMID:11603230
18. Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM Jr. Biological warfare. A historical perspective. JAMA 1997; 278:412-7; PMID:9244333; http://dx.doi.org/10.1001/jama.1997.03550050074036
19. AHFS Drug Information 2006A. Streptomycin Sulfate. The American Society of Health-System Pharmacists 2006:71-73.
20. Woolard MD, Hensley LL, Kawula TH, Frelinger JA. Respiratory Francisella tularensis live vaccine strain infection induces Th17 cells and prostaglandin E2, which inhibits generation of gamma interferon-positive T cells. Infect Immun 2008; 76:2651-9; PMID:18391003; http://dx.doi.org/10.1128/IAI.01412-07
21. Rick Lyons C, Wu TH. Animal models of Francisella tularensis infection. Ann N Y Acad Sci 2007; 1105:238-65; PMID:17395735; http://dx.doi.org/10.1196/ annals.1409.003
22. Elkins KL, Bosio CM, Rhinehart-Jones TR. Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain. Infect Immun 1999; 67:6002-7; PMID:10531260
23. Crane DD, Griffin AJ, Wehrly TD, Bosio CM. B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/ NKT cell responses. J Immunol 2013; 190:2756-66; PMID:23378429; http://dx.doi.org/10.4049/jimmunol.1202697
24. Skyberg JA, Rollins MF, Samuel JW, Sutherland MD, Belisle JT, Pascual DW. IL-17 protects against the Francisella tularensis Live Vaccine Strain, but not against virulent type A F. tularensis. Infect Immun 2013; In press; PMID:23774604; http://dx.doi.org/10.1128/IAI.00203-13.
25. Laws TR, Clark G, D'Elia RV. Differential role for Interleukin-6 during Francisella infection with virulent and vaccine strains. Infect Immun 2013; In press; PMID:23716611; http://dx.doi.org/10.1128/ IAI.00234-13.
26. Crane DD, Warner SL, Bosio CM. A novel role for plasmin-mediated degradation of opsonizing antibody in the evasion of host immunity by virulent, but not attenuated, Francisella tularensis. J Immunol 2009; 183:4593-600; PMID:19752236; http://dx.doi.org/10.4049/jimmunol.0901655
27. Bauler TJ, Chase JC, Bosio CM. IFN-β mediates suppression of IL-12p40 in human dendritic cells following infection with virulent Francisella tularensis. J Immunol 2011; 187:1845-55; PMID:21753150; http://dx.doi.org/10.4049/jimmunol.1100377
28. Bosio CM. The subversion of the immune system by francisella tularensis. Front Microbiol 2011; 2:9; PMID:21687406; http://dx.doi.org/10.3389/fmicb.2011.00009
29. Troyer RM, Propst KL, Fairman J, Bosio CM, Dow SW. Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis. Vaccine 2009; 27:4424-33; PMID:19490961; http://dx.doi.org/10.1016/j.vaccine.2009.05.041
30. Rozak DA, Gelhaus HC, Smith M, Zadeh M, Huzella L, Waag D, et al. CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols. J Immune Based Ther Vaccines 2010; 8:2; PMID:20181102; http:// dx.doi.org/10.1186/1476-8518-8-2
31. Cole LE, Mann BJ, Shirey KA, Richard K, Yang Y, Gearhart PJ, et al. Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge. J Leukoc Biol 2011; 90:787-97; PMID:21750122; http://dx.doi.org/10.1189/jlb.0111014
32. Cowley SC, Elkins KL. Immunity to francisella. Front Microbiol 2011; 2:26; PMID:21687418; http://dx.doi.org/10.3389/fmicb.2011.00026
33. Elkins KL, Cowley SC, Bosio CM. Innate and adaptive immunity to Francisella. Ann N Y Acad Sci 2007; 1105:284-324; PMID:17468235; http://dx.doi.org/10.1196/annals.1409.014
34. Edwards JA, Rockx-Brouwer D, Nair V, Celli J. Restricted cytosolic growth of Francisella tularensis subsp. tularensis by IFN-gamma activation of macrophages. Microbiology 2010; 156:327-39; PMID:19926654; http://dx.doi.org/10.1099/mic.0.031716-0
35. Crane DD, Scott DP, Bosio CM. Generation of a convalescent model of virulent Francisella tularensis infection for assessment of host requirements for survival of tularemia. PLoS One 2012; 7:e33349; PMID:22428026; http://dx.doi.org/10.1371/journal. pone.0033349
36. Elkins KL, Rhinehart-Jones TR, Culkin SJ, Yee D, Winegar RK. Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect Immun 1996; 64:3288-93; PMID:8757866
37. Anthony LS, Ghadirian E, Nestel FP, Kongshavn PA. The requirement for gamma interferon in resistance of mice to experimental tularemia. Microb Pathog 1989; 7:421-8; PMID:2516219; http://dx.doi.org/10.1016/0882-4010(89)90022-3
38. Elkins KL, Colombini SM, Krieg AM, De Pascalis R. NK cells activated in vivo by bacterial DNA control the intracellular growth of Francisella tularensis LVS. Microbes Infect 2009; 11:49-56; PMID:18992838; http://dx.doi.org/10.1016/j.micinf.2008.10.005
39. Melillo AA, Foreman O, Elkins KL. IL-12Rβ2 is critical for survival of primary Francisella tularensis LVS infection. J Leukoc Biol 2013; 93:657-67; PMID:23440500; http://dx.doi.org/10.1189/jlb.1012485
40. Chen W, Kuolee R, Shen H, Bùsa M, Conlan JW. Toll-like receptor 4 (TLR4) plays a relatively minor role in murine defense against primary intradermal infection with Francisella tularensis LVS. Immunol Lett 2005; 97:151-4; PMID:15626487; http://dx.doi.org/10.1016/j.imlet.2004.10.001
41. Collazo CM, Sher A, Meierovics AI, Elkins KL. Myeloid differentiation factor-88 (MyD88) is essential for control of primary in vivo Francisella tularensis LVS infection, but not for control of intra-macrophage bacterial replication. Microbes Infect 2006; 8:779-90; PMID:16513388; http://dx.doi.org/10.1016/j. micinf.2005.09.014
42. Henry T, Kirimanjeswara GS, Ruby T, Jones JW, Peng K, Perret M, et al. Type I IFN signaling constrains IL-17A/F secretion by gammadelta T cells during bacterial infections. J Immunol 2010; 184:3755-67; PMID:20176744; http://dx.doi.org/10.4049/jimmu-nol.0902065
43. Cole LE, Santiago A, Barry E, Kang TJ, Shirey KA, Roberts ZJ, et al. Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways. J Immunol 2008; 180:6885-91; PMID:18453609
44. Forestal CA, Malik M, Catlett SV, Savitt AG, Benach JL, Sellati TJ, et al. Francisella tularensis has a significant extracellular phase in infected mice. J Infect Dis 2007; 196:134-7; PMID:17538893; http://dx.doi.org/10.1086/518611
45. Sandström G, Löfgren S, Tärnvik A. A capsuledeficient mutant of Francisella tularensis LVS exhibits enhanced sensitivity to killing by serum but diminished sensitivity to killing by polymorphonuclear leukocytes. Infect Immun 1988; 56:1194-202; PMID:3356465
46. Löfgren S, Tärnvik A, Carlsson J. Demonstration of opsonizing antibodies to Francisella tularensis by leukocyte chemiluminescence. Infect Immun 1980; 29:329-34; PMID:7216416
47. Löfgren S, Tärnvik A, Bloom GD, Sjöberg W. Phagocytosis and killing of Francisella tularensis by human polymorphonuclear leukocytes. Infect Immun 1983; 39:715-20; PMID:6832815
48. Stenmark S, Sjöstedt A. Transfer of specific antibodies results in increased expression of TNF-α and IL12 and recruitment of neutrophils to the site of a cutaneous Francisella tularensis infection. J Med Microbiol 2004; 53:501-4; PMID:15150328; http://dx.doi.org/10.1099/jmm.0.05352-0
49. Sjöstedt A, Conlan JW, North RJ. Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection. Infect Immun 1994; 62:2779-83; PMID:8005668
50. Conlan JW, KuoLee R, Shen H, Webb A. Different host defences are required to protect mice from primary systemic vs. pulmonary infection with the facultative intracellular bacterial pathogen, Francisella tularensis LVS. Microb Pathog 2002; 32:127-34; PMID:11855943; http://dx.doi.org/10.1006/mpat.2001.0489
51. KuoLee R, Harris G, Conlan JW, Chen W. Role of neutrophils and NADPH phagocyte oxidase in host defense against respiratory infection with virulent Francisella tularensis in mice. Microbes Infect 2011; 13:447-56; PMID:21277990; http://dx.doi.org/10.1016/j.micinf.2011.01.010
52. Kirimanjeswara GS, Golden JM, Bakshi CS, Metzger DW. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol 2007; 179:532-9; PMID:17579074
53. Owen CR, Larson CL. Studies on resistance to bacterial infections in animals infected with Rickettsiae. J Exp Med 1956; 103:753-63; PMID:13319590; http://dx.doi.org/10.1084/jem.103.6.753
54. Claflin JL, Larson CL. Infection-immunity in tularemia: specificity of cellular immunity. Infect Immun 1972; 5:311-8; PMID:4564560
55. Green SJ, Nacy CA, Schreiber RD, Granger DL, Crawford RM, Meltzer MS, et al. Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun 1993; 61:689-98; PMID:8423095
56. Cowley SC, Myltseva SV, Nano FE. Suppression of Francisella tularensis growth in the rat by coinfection with F. novicida. FEMS Microbiol Lett 1997; 153:71-4; PMID:9252574; http://dx.doi.org/10.1111/j.1574-6968.1997.tb10465.x
57. Giron DJ, Schmidt JP, Ball RJ, Pindak FF. Effect of interferon inducers and interferon on bacterial infections. Antimicrob Agents Chemother 1972; 1:80-1; PMID:4670434; http://dx.doi.org/10.1128/AAC.1.1.80
58. Pammit MA, Budhavarapu VN, Raulie EK, Klose KE, Teale JM, Arulanandam BP. Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob Agents Chemother 2004; 48:4513-9; PMID:15561819; http://dx.doi.org/10.1128/AAC.48.12.4513-4519.2004
59. Duckett NS, Olmos S, Durrant DM, Metzger DW. Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect Immun 2005; 73:2306-11; PMID:15784575; http://dx.doi.org/10.1128/IAI.73.4.2306-2311.2005
60. Hajjar AM, Harvey MD, Shaffer SA, Goodlett DR, Sjöstedt A, Edebro H, et al. Lack of in vitro and in vivo recognition of Francisella tularensis subspecies lipopolysaccharide by Toll-like receptors. Infect Immun 2006; 74:6730-8; PMID:16982824; http://dx.doi.org/10.1128/IAI.00934-06
61. Dreisbach VC, Cowley S, Elkins KL. Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon. Infect Immun 2000; 68:1988-96; PMID:10722593; http://dx.doi.org/10.1128/IAI.68.4.1988-1996.2000
62. Kieffer TL, Cowley S, Nano FE, Elkins KL. Francisella novicida LPS has greater immunobiological activity in mice than F. tularensis LPS, and contributes to F. novicida murine pathogenesis. Microbes Infect 2003; 5:397-403; PMID:12737995; http://dx.doi.org/10.1016/S1286-4579(03)00052-2
63. Cole LE, Elkins KL, Michalek SM, Qureshi N, Eaton LJ, Rallabhandi P, et al. Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity. J Immunol 2006; 176:6888-99; PMID:16709849
64. Cole LE, Yang Y, Elkins KL, Fernandez ET, Qureshi N, Shlomchik MJ, et al. Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci U S A 2009; 106:4343-8; PMID:19251656; http://dx.doi.org/10.1073/pnas.0813411106
65. Gidlund M, Orn A, Wigzell H, Senik A, Gresser I. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 1978; 273:759-61; PMID:566386; http://dx.doi.org/10.1038/273759a0
66. Pyles RB, Jezek GE, Eaves-Pyles TD. Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection. Infect Immun 2010; 78:1700-10; PMID:20123717; http://dx.doi.org/10.1128/IAI.00736-09
67. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol 1999; 162:2291-8; PMID:9973506
68. Klinman DM, Conover J, Coban C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun 1999; 67:5658-63; PMID:10531213
69. Gowen BB, Fairman J, Dow S, Troyer R, Wong MH, Jung KH, et al. Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs. Antiviral Res 2009; 81:37-46; PMID:18840471; http://dx.doi.org/10.1016/j.antiviral.2008.09.001
70. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007; 448:501-5; PMID:17618271; http://dx.doi.org/10.1038/nature06013
71. Ireland R, Olivares-Zavaleta N, Warawa JM, Gherardini FC, Jarrett C, Hinnebusch BJ, et al. Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens. PLoS Pathog 2010; 6:e1000921; PMID:20523903; http://dx.doi.org/10.1371/journal. ppat.1000921
72. Lembo A, Pelletier M, Iyer R, Timko M, Dudda JC, West TE, et al. Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J Immunol 2008; 180:7574-81; PMID:18490759
73. Schmidt RL, Filak HC, Lemon JD, Potter TA, Lenz LL. A LysM and SH3-domain containing region of the Listeria monocytogenes p60 protein stimulates accessory cells to promote activation of host NK cells. PLoS Pathog 2011; 7:e1002368; PMID:22072975; http:// dx.doi.org/10.1371/journal.ppat.1002368
74. Meena DK, Das P, Kumar S, Mandal SC, Prusty AK, Singh SK, et al. Beta-glucan: an ideal immunostimulant in aquaculture (a review). Fish Physiol Biochem 2013; 39:431-57; PMID:22965949; http://dx.doi.org/10.1007/s10695-012-9710-5
75. Reynolds JA, Kastello MD, Harrington DG, Crabbs CL, Peters CJ, Jemski JV, et al. Glucan-induced enhancement of host resistance to selected infectious diseases. Infect Immun 1980; 30:51-7; PMID:7439978
76. Holderness J, Schepetkin IA, Freedman B, Kirpotina LN, Quinn MT, Hedges JF, et al. Polysaccharides isolated from Açaí fruit induce innate immune responses. PLoS One 2011; 6:e17301; PMID:21386979; http://dx.doi.org/10.1371/journal.pone.0017301
77. Skyberg JA, Rollins MF, Holderness JS, Marlenee NL, Schepetkin IA, Goodyear A, et al. Nasal Acai polysaccharides potentiate innate immunity to protect against pulmonary Francisella tularensis and Burkholderia pseudomallei Infections. PLoS Pathog 2012; 8:e1002587; PMID:22438809; http://dx.doi.org/10.1371/journal. ppat.1002587
78. Foshay L. Tularemia: A Summary of Certain Aspects of the Disease Including Methods for Early Diagnosis and The Results of Serum Treatment in 600 Patients. Medicine 1940; 19:1-84; http://dx.doi.org/10.1097/00005792-194002000-00001
79. Foshay L. A comparative study of the treatment of tularemia with immune serum, hyperimmune serum and streptomycin. Am J Med 1946; 1:180-8; PMID:20993803; http://dx.doi.org/10.1016/0002-9343(46)90036-8
80. Francis E, Felton LD. Antitularemic serum. Public Health Rep 1942; 57:44-55; http://dx.doi.org/10.2307/4583978
81. Bell JF, Kahn OB. Efficacy of some drugs and biologic preparations as therapeutics agents for tularemia. Archives in Internal Medicine 1945; 75:155-8; http://dx.doi.org/10.1001/archinte.1945.00210270012003
82. Allen WP. Immunity against tularemia: passive protection of mice by transfer of immune tissues. J Exp Med 1962; 115:411-20; PMID:13860583; http://dx.doi.org/10.1084/jem.115.2.411
83. Thorpe BD, Marcus S. Phagocytotsis and intracellular fate of Pasteurella tularensis 3: in vivo studies with passively transferred cells and sera. J Immunol 1965; 94:578-85; PMID:14299033
84. Foshay L, Ruchman I, Nicholes PS. Antitularense serum: correlation between protective capacity for white rats and precipitable antibody content. J Clin Invest 1947; 26:756-60; PMID:16695467; http:// dx.doi.org/10.1172/JCI101858
85. Larson CL. A serum protection test in tularemic infections in white rats. Public Health Rep 1947; 62:1793-9; PMID:18920634; http://dx.doi.org/10.2307/4586386
86. Drabick JJ, Narayanan RB, Williams JC, Leduc JW, Nacy CA. Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine. Am J Med Sci 1994; 308:83-7; PMID:8042659; http://dx.doi.org/10.1097/00000441-199408000-00003
87. Rhinehart-Jones TR, Fortier AH, Elkins KL. Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infect Immun 1994; 62:3129-37; PMID:8039881
88. Stenmark S, Lindgren H, Tärnvik A, Sjöstedt A. Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica. Microb Pathog 2003; 35:73-80; PMID:12901846; http://dx.doi.org/10.1016/S0882-4010(03)00095-0
89. Kubelkova K, Krocova Z, Balonova L, Pejchal J, Stulik J, Macela A. Specific antibodies protect gammairradiated mice against Francisella tularensis infection. Microb Pathog 2012; 53:259-68; PMID:22841607; http://dx.doi.org/10.1016/j.micpath.2012.07.006
90. Pammit MA, Raulie EK, Lauriano CM, Klose KE, Arulanandam BP. Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect Immun 2006; 74:2063-71; PMID:16552035; http://dx.doi.org/10.1128/IAI.74.4.2063-2071.2006
91. Klimpel GR, Eaves-Pyles T, Moen ST, Taormina J, Peterson JW, Chopra AK, et al. Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody. Vaccine 2008; 26:6874-82; PMID:18930100; http://dx.doi.org/10.1016/j.vaccine.2008.09.077
92. Mara-Koosham G, Hutt JA, Lyons CR, Wu TH. Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains. Infect Immun 2011; 79:1770-8; PMID:21282410; http://dx.doi.org/10.1128/ IAI.00605-10
93. Fulop M, Mastroeni P, Green M, Titball RW. Role of antibody to lipopolysaccharide in protection against lowand high-virulence strains of Francisella tularensis. Vaccine 2001; 19:4465-72; PMID:11483272; http:// dx.doi.org/10.1016/S0264-410X(01)00189-X
94. Lavine CL, Clinton SR, Angelova-Fischer I, Marion TN, Bina XR, Bina JE, et al. Immunization with heat-killed Francisella tularensis LVS elicits protective antibody-mediated immunity. Eur J Immunol 2007; 37:3007-20; PMID:17960662; http://dx.doi.org/10.1002/eji.200737620
95. Hickey AJ, Hazlett KR, Kirimanjeswara GS, Metzger DW. Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia. Vaccine 2011; 29:6941-7; PMID:21803089
96. Sutherland MD, Goodyear AW, Troyer RM, Chandler JC, Dow SW, Belisle JT. Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia. Vaccine 2012; 30:4977-82; PMID:22652404; http://dx.doi.org/10.1016/j.vaccine.2012.05.037
97. Lu Z, Roche MI, Hui JH, Unal B, Felgner PL, Gulati S, et al. Generation and characterization of hybridoma antibodies for immunotherapy of tularemia. Immunol Lett 2007; 112:92-103; PMID:17764754; http://dx.doi.org/10.1016/j.imlet.2007.07.006
98. Savitt AG, Mena-Taboada P, Monsalve G, Benach JL. Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy. Clin Vaccine Immunol 2009; 16:414-22; PMID:19176692; http://dx.doi.org/10.1128/CVI.00362-08
99. Conlan JW, Chen W, Shen H, Webb A, KuoLee R. Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb Pathog 2003; 34:239-48; PMID:12732472; http://dx.doi.org/10.1016/S0882-4010(03)00046-9
100. Anderson RV, Crane DD, Bosio CM. Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs. Vaccine 2010; 28:6562-72; PMID:20688042; http://dx.doi.org/10.1016/j.vaccine.2010.07.072
101. Goodyear A, Kellihan L, Bielefeldt-Ohmann H, Troyer R, Propst K, Dow S. Protection from pneumonic infection with burkholderia species by inhalational immunotherapy. Infect Immun 2009; 77:1579-88; PMID:19179415; http://dx.doi.org/10.1128/ IAI.01384-08
102. Hirano T, Kodama S, Kawano T, Maeda K, Suzuki M. Monophosphoryl lipid A induced innate immune responses via TLR4 to enhance clearance of nontypeable Haemophilus influenzae and Moraxella catarrhalis from the nasopharynx in mice. FEMS Immunol Med Microbiol 2011; 63:407-17; PMID:22092567; http:// dx.doi.org/10.1111/j.1574-695X.2011.00866.x
103. Bosio CM, Bielefeldt-Ohmann H, Belisle JT. Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J Immunol 2007; 178:4538-47; PMID:17372012
104. Chase JC, Celli J, Bosio CM. Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4. Infect Immun 2009; 77:180-95; PMID:18981246; http://dx.doi.org/10.1128/IAI.00879-08
105. Sharma J, Li Q, Mishra BB, Pena C, Teale JM. Lethal pulmonary infection with Francisella novicida is associated with severe sepsis. J Leukoc Biol 2009; 86:491-504; PMID:19401387; http://dx.doi.org/10.1189/jlb.1208728